Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind active-controlled study of H062 in primary hypertension inadequately controlled by sacubitril/valsartan monotherapy
CTR20260844Phase 3Active
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Levamlodipine in essential hypertension, sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
Levamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20260844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260844.